Flupenthixol LA-Quetiapine
From Psychiatrienet
| ||||||||||||||||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||||||||||||||||
Switch medication from Flupenthixol_LA to Quetiapine[5][6][7]
Stop Flupenthixol_LA - Day 1: Last depot injection
Start Quetiapine- t= 0 Start dosing 25% of the target dose on the day you normally would have injected the former depot.
- t= 1 x T1/2 of depot approx. 50% of target dose
- t= 2 x T1/2 of depot approx. 75% of target dose
- t= 3 x T1/2 of depot approx. 100% of target dose
- See 'more information' for the T1/2 of this depot
More information- the T1/2 of flupenthixol depot is approximately 21 days.[8]
- ↑ 1.0 1.1 1.2 KNMP; Informatorium Medicamentorum 2023; Monografie "quetiapine" (Dutch)
- ↑ NVZA; Toxicology.org; Monografie 73 (dutch)
- ↑ Woods SW Chlorpromazine equivalent doses for the newer atypical antipsychotics J Clin Psychiatry 2003;64:663-667
- ↑ Drugs.com quetiapine-fumarate
- ↑ Switches are based on literature references on this page and expert opinions of the authors. The authors have used pharmacokinetic and receptor affinity properties to determine the switch schedules
- ↑ Stahl, S. M. (2013). Stahl's essential psychopharmacology: Neuroscientific basis and practical applications (4th ed.). Cambridge University Press.
- ↑ A. Risselada, Switchen van en naar depotantipsychotica - een update; Psyfar, june 2022 nummer 2
- ↑ KNMP Kennisbank, informatorium medicamentorum: Flupentixol
The editors of psychiatrienet.nl take the greatest care to provide up-to-date and accurate information on this site. Nevertheless, mistakes and omissions cannot be entirely excluded. No rights devolve from the information provided. The editors and other providers of information to this site accept no responsibility for the content of this site or for the information provided therein; neither do they accept responsibility for possible damages which may derive from the use of the information on this site or from the linked sites. The editorial board accepts no responsibility for the content of the (linked) sites, for access to them, or for the products and services on these sites, nor for the occurrence of errors, viruses, and/or disruptions in service.
